Dr. Yusuf Saleeby's Health and Wellness Blog. Priority Health Blog.
Thursday, January 19, 2012
Waterborne Diseases During and After Flooding (SC USAR TF-1)
https://www.saleeby.net
https://www.CarolinaHolisticMedicine.com
medical advisory board member UK's LDN Research Trust
Crush Injury / Crush Syndrome / Compartment Syndrome (SC USAR TF-1)
https://www.saleeby.net
https://www.CarolinaHolisticMedicine.com
medical advisory board member UK's LDN Research Trust
Sunday, January 1, 2012
hCG Diet at Wellness One
With mounting obesity epidemiological statistics, it is as important as ever for those that are overweight, obese or suffer from metabolic syndrome (obese, elevated lipids, hypertension and pre-diabetes) to seek a "reduction" in body fat. There are now easy steps in which to achieve quick reductions and establish lifestyle changes for good health. Dr. Saleeby is associated with Wellness One of Myrtle Beach, SC as their new medical director. Wellness One is a health and beauty medical spa that offers the proven hCG diet program and other protocols for weight management.
Watch the video below for more on the hCG Diet Program and contact information for Wellness One and Dr. Saleeby.
Watch the video below for more on the hCG Diet Program and contact information for Wellness One and Dr. Saleeby.
Call for an appointment today: (843) 444-WELL (9355)
As a feature of being an active patient of Dr. Saleeby and WellnessOne, you will be ability to gain access to Xymogen pharmaceutical-grade (physician-only dispensed) supplements.
Additionally, you are granted access to other health provider exclusive supplement lines with a 5% discount (Pure Encapsulations, Perque & Designs for Health DFH) via Emerson Ecologics. Both web sites give you access to high quality, pharm-grade, well engineered lines of dietary supplements. Many of the products the general public cannot purchase or order without access through a healthcare professional, so they are not available over-the-counter. To set up a free account to order is simple; follow the steps on this page:
For discounts (5% and more) on your supplements access code: yms333
Emerson Ecologics is an online distributor of many high quality and exclusive products and I recommend shopping for great deals on this site. You are sure to find any supplement you are looking for on this site. As an active patient of mine you have special access with additional discounts. The account comes with a 5% discount to you on ALL products over and above the discounted prices. You must have my access code to qualify for these discounts and access to some physician exclusive products. You can learn more about what is available by visiting: www.emersonecologics.com. Again as one of our patients you receive an additional 5% discount on your orders. Use Dr. Saleeby’s zip code 29512 and the access code: yms333 or take the shortcut link below (cut and paste into your browser if you get an error message):
Physician exclusive product access:
1) Visit this link: https://store.xymogen.com/PatientSignup.aspx this is a secure web portal to Xymogen.com.
2) Next click on the button that states: No, my doctor has provided me with a code to create a new account.
3) Enter for Code #: staywell (all lower case and no spaces)
4) Enter for Practitioners Last Name: saleeby (lower case)
5) Click on and this will allow you access to set up your own secure account in which you can order Xymogen products on your own. They are drop shipped directly to you. I am not involved in that process. The fact that it is online means you have access 24/7.
If you have questions regarding supplements, what may be the best products for you,
or how and when to take them, Dr. Saleeby is available via email to help answer questions: jpsaleeby@aol.com
https://www.saleeby.net
https://www.CarolinaHolisticMedicine.com
medical advisory board member UK's LDN Research Trust
Wednesday, December 28, 2011
Excessive Cancer Screening in our Elderly Population
Excessive cancer screening in the elderly
Based on the National Health Interview Survey, researchers at the University of Connecticut have reported that patients ≥75 years of age continue to undergo cancer screening in spite of unproven benefit. Specifically, 57%, 62%, 53%, and 56% of patients 75-79 years of age have colorectal, breast, cervical, and prostate screening, respectively. More than 50% of patients > 75 years of age undergo cancer screening based on physician recommendations.
------------------
From MNT blog:
U.S. Preventive Services Task Force guidelines recommend against routinecancer screening, especially for breast, cervical, colorectal and prostate cancer, but adults 75 and older are still receiving regular cancer screenings. The report published in the December 12/26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals, is a part of the journal's Less is More series, the aim is to educate healthcare professionals and patients alike in cuttings costs, but having a better service at the same time.
The authors write as background information in the article :
The authors write as background information in the article :
"In the United States, the number of adults 65 years or older, currently estimated at 36.8 million, is expected to double by the year 2030. Providing high-quality care to this growing population while attempting to contain costs will pose a significant challenge ...While a great deal is known about cancer screening behaviors and trends in young and middle-aged adults, less is known about screening behaviors in older adults from different racial backgrounds."
Keith M. Bellizzi, Ph.D., M.P.H., of the University of Connecticut, Storrs, and colleagues analyzed data from the National Health Interview Survey, an annual in-person nationwide survey used to track health trends in U.S. citizens, to estimate the prevalence of cancer screening among older, racially diverse adults. The study population included 49,575 individuals, 1,697 of whom were 75 to 79 years of age and 2,376 were 80 years of age and older.
Percentages of those reporting cancer screenings are as follows :
- 62 percent Women age 75 to 79 - A mammogram within the past two years.
- 50 percent of women age 80 and older - A mammogram within the past two years.
- 53 percent of women ages 75 to 79 - A Papanicolaou screen (also known as a pap smear or pap test) for cervical cancer within the past three years.
- 38 percent of women ages 80 and older - A pap smear within the past three years.
- 57 percent highest of men and women 75 to 79 - Screenings for colorectal cancer.
- 57 percent of Men 75-79 - Prostate cancer screening.
- 42 percent of Men 80 and older - Prostate cancer screening.
- 40 percent of Men 50-74 and older - Prostate cancer screening
Individuals without a high school diploma were significantly less likely to be screened for breast, cervical and prostate cancer, compared with adults older than 75 years with a college degree. Adults older than 75 years were also significantly more likely to be screened for breast, colorectal, and prostate cancer if a physician recommended the test.
The authors concluded :
"A high percentage of older adults continue to be screened in the face of ambiguity of recommendations for this group ... Prevalence results from this study can serve as a benchmark for progress as we move the science of cancer screening in older, diverse adults forward."
In additional commentary, Louise C. Walter, M.D., of the University of California, San Francisco and San Francisco Veterans Affairs Medical Center, writes that :
"There are no quality measures that address appropriate target rates for cancer screening in persons older than 75 years ...
While at extremes in older age the likelihood of surviving long enough to benefit from potential detection and treatment of asymptomatic cancer becomes quite small and the likelihood of harm becomes quite large irrespective of other factors, Bellizzi et al were not able to calculate screening rates in subgroups older than 85 years owing to the small number participating in the survey ...
Still, the data by Bellizzi et al raise the issue of whether quality measures should address the overuse of cancer screening."
Dr. Walter concludes :
"While it is useful to determine screening rates among persons in whom screening will likely result in net benefit or net harm, between these two groups is a large number of older persons in whom screening offers small or uncertain net benefit ...Written by Rupert Shepherd
For these persons, the decision about whether the potential benefits of screening outweigh the risks is a value judgment that requires informed decision-making ...
While arguments persists about what is the 'right' rate of cancer screening in older persons, it seems clear that the rate of informed decision-making should approach 100 percent."
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
https://www.saleeby.net
https://www.CarolinaHolisticMedicine.com
medical advisory board member UK's LDN Research Trust
Friday, December 9, 2011
Colorectal Cancer Screening
Expert Insights (from Quest Diagnostics patient information page)
A Two-pronged Strategy for Combating Colorectal Cancer
Thursday, March 31st
By: John L. Marshall, MD
Category: Oncology
Colorectal cancer a disease that is preventable, treatable and beatable, and for which early detection is of paramount importance.
Last year, colorectal cancer (CRC) caused an estimated 51,370 deaths in the U.S1.
Most of those deaths could have been prevented.
“When colorectal cancer is detected early and treated, the 5-year relative survival rate is 90%,” notes Dr. John Marshall. “This drops to around 70% for patients diagnosed with regional disease and 12% for those diagnosed with end stage disease2.”
CRC is the third most common cancer in the U.S., but the second leading cause of cancer related deaths3. Dr. Marshall sees two keys to promoting survival from CRC: more widespread screening and more targeted therapy.
A glaring need for more widespread screening
“Colon cancer is one of those diseases where early detection clearly matters,” Dr. Marshall says. “Yet screening rates are terrible. Only 50% of Americans over 50 years of age receive any kind of screening for CRC. That compares with a screening rate for breast cancer of around 70%4. And it’s tragic because regular screening could prevent as many as 60% of CRC deaths.5”
Why are screening rates so low? "Partly because the tests for CRC are difficult for patients to undergo," says Dr. Marshall of colonoscopies and sigmoidoscopies. "Fecal tests help a little, but it's no fun to collect stool. People would rather have a needle stuck in their arm. Better screening techniques and early detection are critical. The field has been moving slowly, which is why recent developments, such as a DNA blood test, are important." This new blood test option, methylated Septin 9, is now available to aid CRC detection for the more than 52 million individuals over 50 years of age, who do not follow guidelines and remain untested.
Genetic profiling for more targeted therapy
In addition to advances in promoting more widespread screening, Dr. Marshall sees promise in targeted testing once CRC is diagnosed. “We give everybody the same treatment up front and just hope that it will help. But we don't know who will benefit.” he says, “We need to get smarter about who gets which drug. We should know which patients are at risk and who needs adjuvant chemotherapy. With stage 2 and 3 patients, for example, deciding who needs adjuvant therapy is critical.”
Dr. Marshall points to genetic profiling as a major step toward evaluating the risks and determining which treatments patients should receive. “Genetic testing is making its way into clinical practice and having an impact on therapy,” he says. “People are getting away from the microscope and looking at certain gene or protein expressions to understand which treatment to select.”
The promise of more effective treatment
Dr. Marshall is optimistic that advances in genetic profiling will lead to more effective therapies. “The only way we’re going to get more effective medicine is through this concept of molecular profiling and targeted drug development.”
"The hope is that this will lead to additional breakthroughs – not necessarily for everyone with colon cancer, but for subsets of patients with specific kinds of colon cancer. I expect we will start to see these efforts come to fruition over the next three to five years."
Testing for CRC via the ColoVantage test can be found online at http://www.estatlabs.com/ (under Cancer markers/screening tests)
References
National Cancer Institute, U.S. National Institutes of Health
www.cancer.gov/cancertopics/types/colon-and-rectal
National Cancer Institute, U.S. National Institutes of Health
http://seer.cancer.gov/statfacts/html/colorect.html#survival
American Cancer Society, Cancer Facts & Figures 2010
American Cancer Society, Breast Cancer Facts & Figures 2010
http://www.cancer.org/acs/groups/content/@nho/documents/document/f861009final90809pdf.pdf
National Health Interview Survey Public Use Data File 2000, 2003, 2005,and 2008.
http://www.estatlabs.com/products/ColoVantage-%28methylated-Septin-9-biomarker-for-colon-cancer-screening%29.html
Author contributing to Expert Insights:
John L. Marshall, MD
Professor of Medicine
Chief, Division of Hematology-Oncology
Director, Clinical Research
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
A Two-pronged Strategy for Combating Colorectal Cancer
Thursday, March 31st
By: John L. Marshall, MD
Category: Oncology
Colorectal cancer a disease that is preventable, treatable and beatable, and for which early detection is of paramount importance.
Last year, colorectal cancer (CRC) caused an estimated 51,370 deaths in the U.S1.
Most of those deaths could have been prevented.
“When colorectal cancer is detected early and treated, the 5-year relative survival rate is 90%,” notes Dr. John Marshall. “This drops to around 70% for patients diagnosed with regional disease and 12% for those diagnosed with end stage disease2.”
CRC is the third most common cancer in the U.S., but the second leading cause of cancer related deaths3. Dr. Marshall sees two keys to promoting survival from CRC: more widespread screening and more targeted therapy.
A glaring need for more widespread screening
“Colon cancer is one of those diseases where early detection clearly matters,” Dr. Marshall says. “Yet screening rates are terrible. Only 50% of Americans over 50 years of age receive any kind of screening for CRC. That compares with a screening rate for breast cancer of around 70%4. And it’s tragic because regular screening could prevent as many as 60% of CRC deaths.5”
Why are screening rates so low? "Partly because the tests for CRC are difficult for patients to undergo," says Dr. Marshall of colonoscopies and sigmoidoscopies. "Fecal tests help a little, but it's no fun to collect stool. People would rather have a needle stuck in their arm. Better screening techniques and early detection are critical. The field has been moving slowly, which is why recent developments, such as a DNA blood test, are important." This new blood test option, methylated Septin 9, is now available to aid CRC detection for the more than 52 million individuals over 50 years of age, who do not follow guidelines and remain untested.
Genetic profiling for more targeted therapy
In addition to advances in promoting more widespread screening, Dr. Marshall sees promise in targeted testing once CRC is diagnosed. “We give everybody the same treatment up front and just hope that it will help. But we don't know who will benefit.” he says, “We need to get smarter about who gets which drug. We should know which patients are at risk and who needs adjuvant chemotherapy. With stage 2 and 3 patients, for example, deciding who needs adjuvant therapy is critical.”
Dr. Marshall points to genetic profiling as a major step toward evaluating the risks and determining which treatments patients should receive. “Genetic testing is making its way into clinical practice and having an impact on therapy,” he says. “People are getting away from the microscope and looking at certain gene or protein expressions to understand which treatment to select.”
The promise of more effective treatment
Dr. Marshall is optimistic that advances in genetic profiling will lead to more effective therapies. “The only way we’re going to get more effective medicine is through this concept of molecular profiling and targeted drug development.”
"The hope is that this will lead to additional breakthroughs – not necessarily for everyone with colon cancer, but for subsets of patients with specific kinds of colon cancer. I expect we will start to see these efforts come to fruition over the next three to five years."
Testing for CRC via the ColoVantage test can be found online at http://www.estatlabs.com/ (under Cancer markers/screening tests)
References
National Cancer Institute, U.S. National Institutes of Health
www.cancer.gov/cancertopics/types/colon-and-rectal
National Cancer Institute, U.S. National Institutes of Health
http://seer.cancer.gov/statfacts/html/colorect.html#survival
American Cancer Society, Cancer Facts & Figures 2010
American Cancer Society, Breast Cancer Facts & Figures 2010
http://www.cancer.org/acs/groups/content/@nho/documents/document/f861009final90809pdf.pdf
National Health Interview Survey Public Use Data File 2000, 2003, 2005,and 2008.
http://www.estatlabs.com/products/ColoVantage-%28methylated-Septin-9-biomarker-for-colon-cancer-screening%29.html
Author contributing to Expert Insights:
John L. Marshall, MD
Professor of Medicine
Chief, Division of Hematology-Oncology
Director, Clinical Research
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
https://www.saleeby.net
https://www.CarolinaHolisticMedicine.com
medical advisory board member UK's LDN Research Trust
Friday, June 3, 2011
Find me on Google's Knol (beta)
https://www.saleeby.net
https://www.CarolinaHolisticMedicine.com
medical advisory board member UK's LDN Research Trust
Subscribe to:
Posts (Atom)
About Me
- Yusuf (JP) Saleeby, MD
- Charleston; Myrtle Beach, SC; Raleigh-Durham, NC; Orlando, FL, GA, NC, SC, VA, FL, United States
- https://www.saleeby.net https://www.CarolinaHolisticMedicine.com medical advisory board member UK's LDN Research Trust